logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Sectors
ASND
Ascendis Pharma A/S
246.23
2 x 246.50
2 x 246.69
bid
ask
-
9.23
3.61%
3 @ 04:00 PM
251.59 +5.36 (2.18%)
Ytd15.47%
1y28.86%
244.12
day range
251.43
186.05
52 week range
282.15
Open250.14Prev Close255.46Low244.12High251.43Mkt Cap15.29B
Vol1.05MAvg Vol662.19KEPS-2.42P/E-101.75Forward P/E22.97
Beta0.39Short Ratio6.52Inst. Own103.94%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning04-3050-d Avg246.86200-d Avg228.021yr Est308.28

ASND News

Ascendis Pharma A/S (ASND) Q2 2026 Earnings Call Transcript
seekingalpha.com
Ascendis Pharma A/S (ASND) Q2 2026 Earnings Call Transcript

Ascendis Pharma A/S (ASND) Q2 2026 Earnings Call Transcript

Ascendis Pharma A/S Q2 Earnings Call Highlights
marketbeat.com
Ascendis Pharma A/S Q2 Earnings Call Highlights

Ascendis Pharma A/S NASDAQ: ASND reported second-quarter 2026 total revenue of EUR 339 million, incl

Ascendis Pharma Reports Second Quarter 2026 Financial Results
globenewswire.com
Ascendis Pharma Reports Second Quarter 2026 Financial Results

– Q2 2026 product revenue of €315 million (+105% Y/Y), comprising €252 million for YORVIPATH ® , €55

Here's How Much $100 Invested In Ascendis Pharma 5 Years Ago Would Be Worth Today
benzinga.com
Here's How Much $100 Invested In Ascendis Pharma 5 Years Ago Would Be Worth Today

Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 5 years by 5.62% on an annua

Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.
globenewswire.com
Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL®

COPENHAGEN, Denmark, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today prov
benzinga.com
Morgan Stanley Maintains Overweight on Ascendis Pharma, Raises Price Target to $275

Morgan Stanley analyst Maxwell Skor maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and

Why Crinetics Stock Soared 99% This Week
247wallst.com
Why Crinetics Stock Soared 99% This Week

Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this we

14 value stocks of companies primed for rapid growth through 2028
marketwatch.com
14 value stocks of companies primed for rapid growth through 2028

Let us begin with a midyear summary of index results that might surprise you in light of the triple-

Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial
globenewswire.com
Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extrem

COPENHAGEN, Denmark, June 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today anno

Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®
globenewswire.com
Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 25

COPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today anno

Ascendis Pharma (ASND) Moves 9.9% Higher: Will This Strength Last?
zacks.com
Ascendis Pharma (ASND) Moves 9.9% Higher: Will This Strength Last?

Ascendis Pharma (ASND) witnessed a jump in share price last session on above-average trading volume.

Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026
globenewswire.com
Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026

COPENHAGEN, Denmark, June 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today anno

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism
globenewswire.com
Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Ad

COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today anno

Touchstone Mid Cap Growth Fund Q1 2026 Portfolio Review
seekingalpha.com
Touchstone Mid Cap Growth Fund Q1 2026 Portfolio Review

The Touchstone Mid Cap Growth Fund (Class A Shares, Load Waived) outperformed its benchmark, the Rus

5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism
globenewswire.com
5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with

– Multi-organ system and quality-of-life benefits sustained through five years of treatment – 82% re

Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026
globenewswire.com
Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026

COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today anno

Ascendis Pharma: Rare Endocrine Compounder Entering Growth Phase (Initiating Buy)
seekingalpha.com
Ascendis Pharma: Rare Endocrine Compounder Entering Growth Phase (Initiating Buy)

Ascendis Pharma is initiated with a buy rating, reflecting its transition to a durable, commercial-s

Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call Transcript
seekingalpha.com
Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call Transcript

Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call Transcript

Ascendis Pharma Reports First Quarter 2026 Financial Results
globenewswire.com
Ascendis Pharma Reports First Quarter 2026 Financial Results

- Q1 2026 revenue of €197 million for YORVIPATH ® and €44 million for SKYTROFA ® - More than 1,000 n

New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years
globenewswire.com
New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains i

COPENHAGEN, Denmark, May 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today annou

Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026
globenewswire.com
Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026

COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today ann

Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028
globenewswire.com
Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due

COPENHAGEN, Denmark, April 21, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today ann

Assetmark Inc. Has $1.83 Million Stake in Ascendis Pharma A/S $ASND
defenseworld.net
Assetmark Inc. Has $1.83 Million Stake in Ascendis Pharma A/S $ASND

Assetmark Inc. raised its holdings in Ascendis Pharma A/S (NASDAQ: ASND) by 48.1% in the undefined q

Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq
globenewswire.com
Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq

COPENHAGEN, Denmark, April 20, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today ann

Earnings Scheduled For February 11, 2026
benzinga.com
Earnings Scheduled For February 11, 2026

Earnings Scheduled For November 12, 2025
benzinga.com
Earnings Scheduled For November 12, 2025
benzinga.com
Earnings Scheduled For August 7, 2025
benzinga.com
Earnings Scheduled For May 1, 2025
benzinga.com
Earnings Scheduled For February 12, 2025
benzinga.com
Earnings Scheduled For November 7, 2023

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings
benzinga.com
Earnings Scheduled For August 10, 2022

  Companies Reporting Before The Bell • Wix.com (NASDAQ:WIX) is estimated to report earnings for i
benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2021

 
benzinga.com
Stocks That Hit 52-Week Highs On Tuesday

Stocks That Hit 52-Week Highs On Tuesday
benzinga.com
Stocks That Hit 52-Week Highs On Thursday

Stocks That Hit 52-Week Highs On Thursday
benzinga.com
Stocks That Hit 52-Week Highs On Wednesday

Stocks That Hit 52-Week Highs On Wednesday
benzinga.com
Stocks That Hit 52-Week Highs On Friday

Stocks That Hit 52-Week Highs On Friday